Publication Forecasts Third Of Australian Biotechs May Close This Year
This article was originally published in PharmAsia News
Executive Summary
Australian biotechs are suffering greatly because of a drop in available investment money. Some report deals that have been canceled, assets that had to be sold and other moves to reduce spending so they can survive. Bioshares, which researches biotechnology companies for a quarterly index, expects nearly a third of the 90 companies on its list to fail this year. Survival Index co-founder David Blake estimates 20 to 30 firms likely to go under and a "leaner, meaner sector" to be the result. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.